| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0022-510X(02)00006-0 |
| P698 | PubMed publication ID | 11897247 |
| P2093 | author name string | Eizo Iseki | |
| Masanori Kato | |||
| Kenji Uéda | |||
| Kenji Kosaka | |||
| Satoshi Miura | |||
| Wami Marui | |||
| Toshiki Nakai | |||
| P2860 | cites work | Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease | Q24321355 |
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies | Q28287237 | ||
| Diffuse Lewy body disease: clinical features in 15 cases | Q33628434 | ||
| Lewy bodies in cerebral cortex, report of three cases | Q34263455 | ||
| Identification of two distinct synucleins from human brain | Q34341909 | ||
| Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop | Q34736093 | ||
| Accumulation of NACP/alpha-synuclein in lewy body disease and multiple system atrophy | Q35456966 | ||
| Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system | Q39992564 | ||
| Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly | Q43528491 | ||
| Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease | Q48225035 | ||
| Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease | Q48315686 | ||
| Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity | Q48463677 | ||
| Hippocampal pathology in diffuse Lewy body disease using ubiquitin immunohistochemistry | Q48655029 | ||
| Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD | Q48669050 | ||
| Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease | Q48964056 | ||
| Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies | Q48964629 | ||
| A direct demonstration of the perforant pathway terminal zone in Alzheimer's disease using the monoclonal antibody Alz-50 | Q53192984 | ||
| Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease | Q64861832 | ||
| Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease | Q73571882 | ||
| Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry | Q73816088 | ||
| P433 | issue | 2 | |
| P921 | main subject | dementia | Q83030 |
| patient | Q181600 | ||
| pathology | Q7208 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 153-159 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Journal of the Neurological Sciences | Q6296168 |
| P1476 | title | Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies | |
| P478 | volume | 195 |
| Q47779956 | Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study |
| Q35380017 | Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly |
| Q33997481 | Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy |
| Q91845936 | Analysis of α-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies |
| Q34575415 | Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. |
| Q35624697 | Autophagy in dementias |
| Q30577415 | Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity |
| Q35593764 | Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies |
| Q33202814 | Biomarker identification in neurologic diseases: improving diagnostics and therapeutics |
| Q37038032 | Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains |
| Q47923287 | Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias |
| Q33917271 | Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy |
| Q34806323 | Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both |
| Q45291590 | Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease |
| Q44388400 | Degeneration of tyrosine hydroxylase-immunoreactive neurons in the cerebral cortex and hippocampus of patients with dementia with Lewy bodies |
| Q35944960 | Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis |
| Q33899875 | Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. |
| Q53261140 | Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. |
| Q48299267 | Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies |
| Q35996880 | Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation |
| Q36063245 | Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons |
| Q37209166 | Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient |
| Q50710454 | Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. |
| Q48321770 | Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies |
| Q35843937 | Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype |
| Q48263978 | Lewy body variant of Alzheimer's disease or cerebral type lewy body disease? Two autopsy cases of presenile onset with minimal involvement of the brainstem |
| Q36626757 | Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease |
| Q42610053 | Many roads to Parkinson's disease neurodegeneration: head trauma-a road more traveled than we know? |
| Q36575028 | Mechanisms and models of alpha-synuclein-related neurodegeneration. |
| Q52363911 | Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease. |
| Q37350413 | Molecular and cellular biology of synucleins |
| Q35078396 | Myoclonus and neurodegenerative disease--what's in a name? |
| Q37693339 | Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff |
| Q48760446 | Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies |
| Q48263744 | Perirhinal accumulation of neuronal alpha-synuclein in a multiple system atrophy patient with dementia. |
| Q33608943 | Preclinical polymodal hallucinations for 13 years before dementia with Lewy bodies |
| Q48279657 | Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. |
| Q37554972 | Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. |
| Q49353206 | Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies |
| Q34568456 | Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study |
| Q48321578 | Relationship between regional cerebral blood flow and neuropsychiatric symptoms in dementia with Lewy bodies |
| Q35572836 | Striatal blood-brain barrier permeability in Parkinson's disease |
| Q27004240 | The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis |
| Q28068464 | The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease |
| Q38139561 | The function of α-synuclein |
| Q35949235 | The insular lobe of Reil--its anatamico-functional, behavioural and neuropsychiatric attributes in humans--a review |
| Q35600279 | The mesopontine rostromedial tegmental nucleus: an integrative modulator of the reward system |
| Q44263262 | Three presenile patients in which neuropsychological and neuroimaging examinations suggest possible progression to dementia with Lewy bodies |
| Q91559574 | Transmission of α-synuclein seeds in neurodegenerative disease: recent developments |
| Q36772321 | Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors |
| Q90028599 | Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging |
| Q37376010 | Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction |
| Q42510607 | Wild-Type Monomeric α-Synuclein Can Impair Vesicle Endocytosis and Synaptic Fidelity via Tubulin Polymerization at the Calyx of Held |
Search more.